Regulatory milestones

Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $2.50 (10%) to $28.12 on Friday after FDA approved an NDA for Ampyra dalfampridine (formerly Fampridine-SR) to improve walking ability in patients with multiple sclerosis (MS). Acorda was up $2.86 (11%) for the week.

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) was off $0.43 to $28.69 last week, while BioSpecifics Technologies Corp. (NASDAQ:BSTC) lost $0.67 to $27.08 after EMEA accepted for filing an MAA from Pfizer Inc. (NYSE:PFE) for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand...